Abstract
The therapeutic potential of cannabinoids has been studied and investigated through centuries, although many interesting discoveries have emerged from this field in the past decades. Indeed, peripheral analgesic effects of cannabinoids are a new avenue of treatment since they are avoiding the deleterious central side effects of systemic administration. Recently, it has been demonstrated that cannabinoid receptors (more specifically CB1 and CB2 receptors) and their endogenous ligands are present at the peripheral level, especially in different layers of skin, and mostly, in the epidermis and dermis. Those findings are reinforcing and confirming the efficacy of peripheral administration of cannabinoids used to alleviate pain in many different animal models. However, many studies have shown that the endocannabinoid system interacts with other receptors and pathways to modulate pain at the peripheral level. Thereof, the main goal of this review is to explain, in a better way, the different interactions regarding the cannabinoid system with other cellular components of its environment, its involvement in the modulation of pain at the peripheral level and, more precisely, in different layers of the skin.
Keywords: Cannabinoids, endocannabinoids, anandamide, primary afferent neurone, analgesia, pain, opioids
Current Molecular Pharmacology
Title: The Role of the Endogenous Cannabinoid System in Peripheral Analgesia
Volume: 2 Issue: 1
Author(s): Josee Guindon and Pierre Beaulieu
Affiliation:
Keywords: Cannabinoids, endocannabinoids, anandamide, primary afferent neurone, analgesia, pain, opioids
Abstract: The therapeutic potential of cannabinoids has been studied and investigated through centuries, although many interesting discoveries have emerged from this field in the past decades. Indeed, peripheral analgesic effects of cannabinoids are a new avenue of treatment since they are avoiding the deleterious central side effects of systemic administration. Recently, it has been demonstrated that cannabinoid receptors (more specifically CB1 and CB2 receptors) and their endogenous ligands are present at the peripheral level, especially in different layers of skin, and mostly, in the epidermis and dermis. Those findings are reinforcing and confirming the efficacy of peripheral administration of cannabinoids used to alleviate pain in many different animal models. However, many studies have shown that the endocannabinoid system interacts with other receptors and pathways to modulate pain at the peripheral level. Thereof, the main goal of this review is to explain, in a better way, the different interactions regarding the cannabinoid system with other cellular components of its environment, its involvement in the modulation of pain at the peripheral level and, more precisely, in different layers of the skin.
Export Options
About this article
Cite this article as:
Guindon Josee and Beaulieu Pierre, The Role of the Endogenous Cannabinoid System in Peripheral Analgesia, Current Molecular Pharmacology 2009; 2 (1) . https://dx.doi.org/10.2174/1874467210902010134
DOI https://dx.doi.org/10.2174/1874467210902010134 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Effects Elicited In Vitro by Red Wine on Human Healthy Peripheral Blood Mononuclear Cells: Potential Therapeutical Application of Polyphenols to Diet-Related Chronic Diseases
Current Pharmaceutical Design Application of Charge Transfer Reactions for the Quantitative Spectrophotometric Determination of Cyclophosphamide in Pure and Pharmaceutical Formulation
Current Pharmaceutical Analysis Human Amnion-Derived Cells: Prospects for the Treatment of Lung Diseases
Current Stem Cell Research & Therapy Development and Validation of a Hypoxia-related Prognostic Model for Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot topic: Hepatocyte Growth Factor and cMET, New Development in Cancer Therapies (Guest Editors: T.A. Martin and W.G. Jiang)]
Anti-Cancer Agents in Medicinal Chemistry Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry Editorial (Thematic Issue: Clinical Advances in Immuno-oncology – Progress Towards Selective Cure)
Current Molecular Pharmacology Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based “Triple Therapy” Experience in Southern Italy
Reviews on Recent Clinical Trials Anti-acne Treatment using Nanotechnology based on Novel Drug Delivery System and Patents on Acne Formulations: A Review
Recent Patents on Nanotechnology Patent Selections
Recent Patents on DNA & Gene Sequences Graphical Abstracts
Inflammation & Allergy - Drug Targets (Discontinued) The Use of TNF Family Ligands and Receptors and Agents which Modify their Interaction as Therapeutic Agents
Current Drug Targets Biomaterials in Bearing Surface for Total Hip Arthroplasty: State of the Art
Recent Patents on Biomedical Engineering (Discontinued) Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a<sup>-/-</sup> Model
Current Pharmaceutical Design A Systematic Review of the Potential Herbal Sources of Future Drugs Effective in Oxidant-Related Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Nitric Oxide, Malnutrition and Chronic Renal Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Therapies in OA
Current Drug Targets Human Defensins: Synthesis and Structural Properties
Current Pharmaceutical Design Editorial (Thematic Issue: Protein-protein interaction: from interface to interaction network)
Current Pharmaceutical Design Association of microRNA-146a rs57095329 Polymorphism with Susceptibility to Primary Gout in a Chinese Han Population
Current Rheumatology Reviews